- 1633.984
- +8.128+0.50%
$100 Invested In This Stock 15 Years Ago Would Be Worth $1,400 Today
Icon (NASDAQ:ICLR) has outperformed the market over the past 15 years by 6.88% on an annualized basis producing an average annual return of 19.66%. Currently, Icon has a market capitalization of $26.3
Top Shorted S&P 500 Industrial Stocks at May End
Quest Completes Acquisition of PathAI Assets
Peering Into Quest Diagnostics's Recent Short Interest
Quest Diagnostics's (NYSE:DGX) short percent of float has fallen 3.47% since its last report. The company recently reported that it has 2.70 million shares sold short, which is 2.78% of all regular sh
Mizuho Starts Charles River Labs at Neutral, Cites Near-term Challenges
AbbVie, Amazon, Goldman Sachs And 2 Major Health Care Stocks On CNBC's 'Final Trades'
On CNBC's "Halftime Report Final Trades," Jim Lebenthal of Cerity Partners said AbbVie Inc. (NYSE:ABBV) is a very solid pharmaceutical company. The company has good dividend yield and attractive valua
The Analyst Verdict: Charles River In The Eyes Of 4 Experts
4 analysts have shared their evaluations of Charles River (NYSE:CRL) during the recent three months, expressing a mix of bullish and bearish perspectives.The following table encapsulates their recent
IQVIA Hldgs Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/06/2024 23.34% Goldman Sachs → $270 Initiates Coverage On → Buy 05/03/2024 14.21% Evercore ISI Group $2
(IQV) - Analyzing IQVIA Hldgs's Short Interest
IQVIA Hldgs's (NYSE:IQV) short percent of float has risen 3.83% since its last report. The company recently reported that it has 3.04 million shares sold short, which is 1.9% of all regular shares tha
Sell Ideas in Staples and Health Care - Oppenheimer
Icon Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/31/2024 13.65% Baird $363 → $367 Maintains Outperform 04/26/2024 8.08% TD Cowen $343 → $349 Maintains B
Forecasting The Future: 4 Analyst Projections For Labcorp Holdings
Across the recent three months, 4 analysts have shared their insights on Labcorp Holdings (NYSE:LH), expressing a variety of opinions spanning from bullish to bearish.The following table encapsulates
Piper Sandler's Actionable Trading Ideas: 3 Positive, 3 Negative
Labcorp Holdings Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/30/2024 25.91% JP Morgan $261 → $243 Maintains Overweight 04/26/2024 32.12% Truist Securities $270 → $2
Quest Diagnostics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/30/2024 11.68% JP Morgan $152 → $155 Maintains Neutral 04/25/2024 3.75% Barclays $138 → $144 Maintains
Here's How Much $1000 Invested In Icon 10 Years Ago Would Be Worth Today
Icon (NASDAQ:ICLR) has outperformed the market over the past 10 years by 11.78% on an annualized basis producing an average annual return of 22.28%. Currently, Icon has a market capitalization of $26.
ICON Reaffirms FY24 Revenue Guidance Of $8.48B-$8.72B Vs $8.64B Est.; Raises FY24 EPS From $14.65-$15.15 To $14.75-$15.25 Vs $14.98 Est.
Full-year 2024 revenue guidance is reaffirmed in the range of $8,480 - $8,720 million, representing a year over year increase of 4.4% to 7.4%. Full-year 2024 adjusted earnings per share* guidance is n
ICON Updates FY24 Guidance To Incorporate Its Recent Debt Refinancing Expected To Result In A Net Interest Expense Of $200M-$210M For FY24, From The Previous Range Of $200M-$230M
Financial OutlookICON is updating its full-year 2024 guidance to incorporate its recent debt refinancing, including the impact of the successful $2 billion investment grade bond offering closed in ear
Charles River Introduces Its Vector Tech Transfer Program To Safeguard Gene Therapy Development
Fast Track and Modular frameworks facilitate product development continuity via seamless process transfer to the Company's viral vector Center of ExcellenceCharles River Laboratories International, In
Mizuho Starts Fortrea at Neutral, Cites Low Near-term Earnings Visibility